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Cachexia remains an underdiagnosed and undertreated,
complex condition which includes ‘objective’ components
(e.g. inadequate food intake, weight loss, inactivity, loss of
muscle mass and metabolic derangements, inducing
catabolism)1,2 and ‘subjective’ components (e.g. anorexia,
early satiety, taste alterations, chronic nausea, distress, fa-
tigue and loss of concentration). Approximately half of all
patients with advanced cancer experience cachexia.
Comprehensive treatment requires a multitargeted and
multidisciplinary approach aimed at evaluating the objec-
tive signs and relieving the symptoms. The primary goal is to
meet the physiological and psychological needs of the pa-
tient. This includes providing energy, nutritional substrates
and anabolic stimuli, as well as compassionate support to
address dysfunctions associated with the emotional and
social aspects of eating. Nutritional and metabolic in-
terventions range from dietary counselling to pharmaco-
logical agents and parenteral nutrition (PN). The
invasiveness of an intervention needs to be chosen and
tailored, weighing the benefits and risks for each individual
patient. This is of increasing importance with advancing
disease and when approaching end of life. In this sense,ondence to: ESMO Guidelines Committee, ESMO Head Office, Via
CH-6900 Lugano, Switzerland
linicalguidelines@esmo.org (ESMO Guidelines Committee).
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- Issue 3 - 2021nutrition is an essential component of supportive, rehabil-
itative and palliative care. During the patient’s trajectory
towards end of life, however, the focus of nutritional care
needs to change. During anticancer treatment, patients
should be offered all available nutritional therapeutic op-
tions, if required, whereas during the last weeks of life, care
should focus increasingly on immediate symptomatic relief
(Figure 1).
In general, if anticancer treatment is effective, this often
results in an improvement in cachectic signs and symp-
toms,3 while ineffective anticancer treatment may increase
catabolism and aggravate cachexia.4
This European Society for Medical Oncology (ESMO)
Clinical Practice Guideline (CPG) on cancer cachexia has
been designed for medical oncologists who frequently care
for patients with cancer cachexia in their clinical practice.
The goal is to provide answers to questions regarding the
diagnosis and treatment of cachexia-related physical and
psychological problems, relying on evidence-based infor-
mation whenever possible. A similar approach has recently
been published by the American Society of Clinical
Oncology (ASCO).5
This CPG provides recommendations on overt cachexia as
well as at-risk settings. Evidence to support these recom-
mendations has been derived from trials studying the evo-
lution of the signs and symptoms of cachexia. Whereas
today we define cachexia on a pathophysiological basis to be
malnutrition in the presence of disease-related metabolic
alterations,6-8 historically, clinical trials used varying and
inconsistent combinations of inclusion criteria. A summaryhttps://doi.org/10.1016/j.esmoop.2021.100092 1
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Figure 1. Invasiveness of interventions relative to expected survival.
ONS, oral nutritional supplement.
ESMO Open J. Arends et al.of inclusion criteria for all clinical trials, guidelines and sys-
tematic review articles reported in this CPG is therefore
provided for reference in Supplementary Tables S1, S2 and
Supplementary Figures S1AeS1C, available at https://doi.
org/10.1016/j.esmoop.2021.100092.Recommendations
 Regular nutritional screening and nutritional support,
including (if necessary) enteral nutrition or PN, is recom-
mended in all patients receiving anticancer treatment
and in those with an expected survival of more than a
few months [V, B].
 In patients with an expected survival of less than a few
months, a decrease in the invasiveness of nutritional in-
terventions is recommended, with dietary counselling
and oral supplements preferred, if possible [V, B].
 In patients with an expected survival of less than a few
weeks, comfort-directed care is the recommended
approach, including alleviating thirst, eating-related
distress and other debilitating symptoms [V, B].DEFINITION AND IMPACT OF CACHEXIA
Weight loss with depletion of fat stores and muscle mass
frequently develop in patients with advanced cancer and
may be the first signs leading to the diagnosis of a malig-
nancy. A number of pathophysiological derangements may
result in weight loss and several factors often occur at the
same time, including impaired food intake, reduction in
physical activity and its associated anabolic effects as well
as metabolic changes leading to systemic inflammation and
activation of catabolism (see Figure 2). Patients with
depleted resources are at an increased risk of anticancer
treatment-related toxicity and a lower quality of life
(QoL); toxicity results in shorter treatment times, lower2 https://doi.org/10.1016/j.esmoop.2021.100092dose intensity, lower response rates, increased surgical
complications and higher mortality.7
Although used since the 19th century, a disconcerting
number of definitions have been proposed for the term
‘malnutrition’. To avoid confusion, we recommend following
the recent suggestion of the Global Leadership Initiative in
Malnutrition (GLIM)8 that defines malnutrition by the
presence of a positive malnutrition screening test, one of a
list of phenotypical and one of two aetiological criteria (see
Table 1). Aetiological criteria are used to differentiate
starvation-type (with protein-sparing metabolism9) from
cachexia-type or disease-associated malnutrition, charac-
terised by accelerated protein breakdown and the hallmark
of muscle loss driven by metabolic changes, most notably
systemic inflammation.6,10,11
Tissue injury induces inflammation;12 in cancer, malig-
nant and stromal immune cells may contribute to a chronic
inflammatory state13 leading to complex catabolic
sequelae.14 Systemic inflammation has been extensively
and reliably associated with poor clinical outcome. A widely
validated and simple score to categorise systemic inflam-
mation is the modified Glasgow Prognostic Score, based on
C-reactive protein and serum albumin (C-reactive protein
normal: 0; raised C-reactive protein and normal albumin: 1;
raised C-reactive protein and low albumin: 2). This score is
highly prognostic of clinical outcome.15
Thus, the pathophysiology of cachexia is currently under-
stood as host-tumour interactions redirecting metabolism
and driving the brain to reduce appetite, cause alterations in
taste and smell, impact gastrointestinal (GI) autonomic
function, induce fatigue and decrease daily physical activity
(see Section 2 of the Supplementary Material, available
at https://doi.org/10.1016/j.esmoop.2021.100092). While
inadequate food intake is a major driver of weight loss,7
metabolic changes and reduced activity contribute to loss
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Figure 2. The complexity of causes contributing to weight loss in patients with cancer.
GI, gastrointestinal.
J. Arends et al. ESMO OpenDuring the last decade, low muscle mass (sarcopenia; see
definition in Table 117) has been identified as a central
factor impacting clinical outcome, and anticancer agents
have been recognised as an important cause of sarcope-
nia.18 In clinical practice, it is highly relevant that loss of
muscle strength and muscle mass may appear early and
before the occurrence of a clinically apparent weight loss
and that it may coexist with obesity and hence be present in
patients with a high body mass index (sarcopenic obesity).19
Cachexia may evolve over time and it has been proposed
to differentiate early phases without discernible weight loss
(pre-cachexia) from advanced or refractory stages6 (see
Figure 3). In cachectic patients, the most common GI
symptoms are anorexia and early satiety, nausea, bloating,
taste alterations, xerostomia, dysphagia and constipation. In
addition, other secondary nutrition impact symptoms may
occur, such as breathlessness, severe fatigue, etc. Nutrition
impact symptoms are commonly experienced and are
associated with a poor QoL and performance status (PS).20Recommendation
 Defining cachexia as disease-related malnutrition based
on the GLIM definition of malnutrition and the presence
of systemic inflammation is recommended [V, A].Volume 6 - Issue 3 - 2021SCREENING AND ASSESSMENT OF CACHEXIA
To ensure access to adequate nutritional and metabolic care
for all patients, it is important to:
 Detect at-risk patients by routinely implementing a
standardised screening procedure.
 Assess all at-risk patients for their nutritional and metabolic
status as well as all impairments endangering this status.7Malnutrition risk screening
Nutritional risk screening should be carried out regularly in
all cancer patients undergoing anticancer treatment and in
those with an expected survival of more than a few (i.e. 3-6)
months. In patients with an expected survival of less than a
few months, screening for eating-related distress should be
carried out (Figure 4).
While there is no general agreement on the ‘best’
screening tool,21,22 the following are suggested: Malnutrition
Universal Screening Tool (MUST), Nutrition Risk Screening
2002 (NRS-2002), Short Nutritional Assessment Questionnaire
(SNAQ) and the Malnutrition Screening Tool (MST).21 Other
more complex tools like the Patient-Generated Subjective
Global Assessment (PG-SGA) may be included in assessment
procedures.https://doi.org/10.1016/j.esmoop.2021.100092 3
Table 1. Definitions of major terms
Term Definition and criteria
Malnutrition Defined by three criteria: a positive malnutrition screening




Malnutrition risk predicted by a validated




Loss of or low body mass as defined by at
least one of the following:
A1: weight loss >5% in 6 months
A2: body mass index below 20 kg/m2
A3: low muscle mass
Aetiological
criteria
Reduced food availability (B1) and/or
increased catabolism (B2)
B1 (starvation type): reduction in food
availability
B1a: food intake <50% for >1 week
B1b: any reduction in food intake for >2
weeks
B1c: chronic malabsorption
B2 (cachexia type): increased acute or
chronic systemic inflammation
Cachexia A disease-related subtype of malnutrition identified by










B2 (systemic inflammation; described
above)
Sarcopenia Defined by two criteria: low muscle strength combined with




Criterion A Low muscle strength
Criterion B Low muscle mass or quality
MST, Malnutrition Screening Tool; MUST, Malnutrition Universal Screening Tool; NRS-
2002, Nutrition Risk Screening 2002; SARC-F, Strength, Assistance with walking, Rise
from a chair, Climb stairs and Falls; SNAQ, Short Nutritional Assessment
Questionnaire.
ESMO Open J. Arends et al.Assessment of nutritional status
All patients diagnosed as being at-risk following malnutri-
tion screening should be referred to a nutrition expert
for assessment of nutritional and metabolic status and
evaluation of food intake impairment and GI function.7
Assessing nutritional status should include objective
assessment of the following (see Table 2 for recommended
parameters):
 Body weight (BW).
 Weight change during the preceding months.
 Body composition with a focus on muscle mass.6
 Food intake with a focus on energy and protein.
 PS [Eastern Cooperative Oncology Group (ECOG)/World
Health Organization (WHO)].
 Information regarding the presence and degree of sys-
temic inflammation.7
An assessment of factors that are impeding or that might
interfere with maintaining nutritional status should include
evaluation of:4 https://doi.org/10.1016/j.esmoop.2021.100092 Nutrition impact symptoms, such as anorexia, nausea,
taste and smell alterations, mucositis, constipation,
dysphagia, chronic pain, abdominal pain (e.g. cramping)
and diarrhoea, as well as aspects of GI function poten-
tially responsible for these symptoms.
 Fatigue, physical activity, shortness of breath and psy-
chosocial distress.7
Assessment should focus on modifiable factors that can
be addressed by an intervention. The systematic use of a
nutritional impact checklist has been shown to trigger more
therapeutic interventions, leading to better symptom con-
trol and subsequently to a better nutritional intake.23 Based
on these findings, a tailored intervention can be started,
including nutritional advice, alleviating nutritional impact
factors and targeting any other factors that may hinder an
adequate nutritional intake (such as social support or
financial difficulties).Recommendations
 Standardised screening for nutritional risk at regular in-
tervals is recommended for all patients undergoing anti-
cancer treatment and those with a life expectancy of at
least a few (i.e. 3-6) months; a validated screening tool
should be applied [V, B].
 Offering supportive nutritional advice and education
about cachexia, as well as psychological and palliative
support, is recommended for all patients experiencing
eating-related distress [V, B].
 Patients found to be at no immediate risk of malnutrition
by screening should be re-screened at regular intervals
(typically every 3 months or at staging for anticancer
treatment) or, in cases where anticancer treatment
with a high risk of inducing malnutrition is planned
(e.g. combined-modality treatments, high-dose chemo-
therapy, highly emetogenic agents), prophylactic nutri-
tional support should be considered [V, B].
 For patients identified as being at nutritional risk, an
objective assessment of nutritional and metabolic status
(including weight, weight loss, body composition, inflam-
matory state, nutritional intake and physical activity) and
examination for the presence of factors interfering
with the maintenance or improvement of this status
(including nutrition impact symptoms, GI dysfunction,
chronic pain and psychosocial distress) is recommended.
Repeating nutritional assessments at regular intervals,
typically monthly, is also recommended to guide multi-
component anti-cachexia treatment [V, B].DECIDING ON CACHEXIA TREATMENT
The relative importance of cachexia-related subjective and
objective signs and symptoms may change during the tra-
jectory of the disease; changes in body resources and
metabolic pattern as well as impairment of physical per-
formance are essential targets in patients undergoing anti-
cancer treatment, but they lose their importance near end
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Figure 4. Screening and assessment of nutritional and metabolic risk for cachexia.
GI, gastrointestinal; MNA-sf, Mini Nutritional Assessment short form; MST, Malnutrition Screening Tool; MUST, Malnutrition Universal Screening Tool; NRS-2002,





(>2% if sarcopenia or body mass index <20)
Advanced cancer refractory to
anticancer treatment
Expected survival <3 months
End-of-life phase
Pre-cachexia Cachexia Advanced cachexia
Metabolic changes, usually associated with symptoms, e.g. anorexia
Loss of cell mass (body weight, muscle mass)
Normal Death
Figure 3. Evolution of cancer cachexia.
Adapted from Fearon et al.6
J. Arends et al. ESMO Openand alleviated as much as possible throughout the life of
every patient with the involvement of his/her family
members and caregivers.Volume 6 - Issue 3 - 2021Predicting the overall survival (OS) and end of life of in-
dividual patients is inherently difficult, inaccurate and often
overly optimistic.24 Probability estimates (i.e. prediction ofhttps://doi.org/10.1016/j.esmoop.2021.100092 5
Table 2. Parameters of comprehensive cachexia assessment and recom-
mended tools
Category Parameter Recommended tool(s)
Nutritional
status
Whole body status BW
Weight loss % of usual healthy weight
Food intake % of required amount
Energy and protein intakea Kcal/kg/day, g/kg/day
Micronutrient or
macronutrient deficienciesa
Food diary or 24-hour recall
and software-based analysis
Body compositiona Anthropometry
BIA, CT or DEXA133
Metabolic
status
Systemic inflammation Modified Glasgow
Prognostic Score15





Dependency Northwick Park Dependency
Score135
Grip strengtha Dynamometry
Gait speeda 4-metre gait speed test136
Nutritional
barriers
Nutrition impact symptoms PG-SGA137
Nutritional impact
checklist23




















Possible adverse effects on
appetite, GI tract, central
nervous system, fatigue
Pharmacological counselling
Tumour status Extent and activity of
cancer disease, likelihood
of response to anticancer
treatment
Oncological counselling
ADL, activities of daily living; BIA, bioelectrical impedance analysis; BW, body weight;
CT, computed tomography; DEXA, dual X-ray absorptiometry; ECOG, Eastern Coop-
erative Oncology Group; ESAS, Edmonton Symptom Assessment System; EORTC,
European Organisation for Research and Treatment of Cancer; FAACT, Functional
Assessment of Anorexia/Cachexia Treatment; GI, gastrointestinal; PG-SGA, Patient-
Generated Subjective Global Assessment; PS, performance status; QLQ-CAX24,
cachexia-specific quality of life questionnaire; WHO, World Health Organization.
a If available and appropriate, depending on resources available and the patient’s
capability.
Table 3. Criteria to consider when deciding on nutritional and metabolic
interventions
Benefit possible Benefit uncertain
Ongoing anticancer treatment Approaching end of life
No or only minimal inflammation
or inflammation responsive to
treatment
Persistent, severe and unresponsive
inflammation
No or only slow and mild weight
loss
Rapid and severe weight loss
refractory to anticancer treatment
Stable or only slowly progressing
cancer
Rapidly progressing cancer without
reasonable treatment options
Good chance of intervention to
improve the patient’s well-being
No realistic chance that the
intervention will improve the
situation of the patient
Patient is aware of the prognosis
and of the positive/negative effects
of the intervention
Patient is not fully aware of the
prognosis or the positive/negative
effects of the intervention
Strong wish of the patient to
accomplish or reach an individual
goal
Patient is preparing for dying
Patient is motivated and feels very
little inconvenience considering the
planned nutritional intervention
Patient feels the nutritional
intervention to be burdensome and
is unmotivated/unwilling to start the
intervention
Patient is able and motivated to
be physically active
Immobilised patient without urge to
be or to become active
Severely impaired food tolerance Only mildly impaired food intake
ESMO Open J. Arends et al.the chances of a patient being alive at a certain time point)
are more accurate,25 as are simple scores based on in-
flammatory markers.26
Dealing with uncertainties in prognosis requires contin-
uous, honest and empathic communication with the patient
and his/her caregivers as well as comprehensive discussions
among all members of the medical team to recognise and
repeatedly re-evaluate the indication for individual anti-
cachexia interventions, given that each intervention is
associated with different risks and burdens. Table 3 pro-
vides a summary of key criteria to consider when discussing
the initiation of nutritional interventions with the patient
and family/caregivers.Choosing anti-cachexia treatment options: prioritising
multimodal care
Given the complex and multifaceted contributors to
cachexia, anti-cachexia treatment must be based on a6 https://doi.org/10.1016/j.esmoop.2021.100092comprehensive assessment of the patient’s situation and an
evaluation of reasonable, available treatment options,
resulting in a personalised, multitargeted and multimodal
approach.27
Food intake may be compromised by many factors and
secondary to nutrition impact symptoms, some of which
may be amenable to treatment. If, after alleviating these
factors, food intake is still inadequate, nutrition-based in-
terventions should be initiated.
Compared with providing energy and nutrients by nutri-
tional interventions, modulating metabolic derangements is
more complex. The evolution of insulin resistance28 and
anabolic resistance29 impair the maintenance of whole-
body muscle mass. Thus, interventions to decrease catab-
olism and increase anabolic pathways include the provision
of adequate amounts of energy and proteins; muscle
training; pharmacological agents to increase appetite,
diminish systemic inflammation and stimulate muscle
growth; and psychosocial interactions to alleviate distress.
When anticancer treatment is offered to a cachectic pa-
tient, in addition to carefully adjusting the dosing, the in-
tensity of multimodal supportive management needs to be
enhanced, encompassing nutrition, physical exercise,
anti-catabolic and anti-inflammatory treatment, as well as
psychological and social support. In the cachectic cancer
patient who is physically unfit for further oncological ther-
apy, a key challenge is to decide whether to maintain or
reduce the intensity of multimodal supportive manage-
ment. Nutritional support and physiotherapy may be
offered on an individual basis while carefully monitoring
individual goals and QoL. During the last weeks of life, it is
essential to provide relief from eating-related distress and
weight loss-related distress, strategies to cope with
impending death and compassionate communication with
patients and family.Volume 6 - Issue 3 - 2021
J. Arends et al. ESMO OpenRecommendations
 Every patient with cachexia should be offered interven-
tions with the goal of either improving or alleviating
the consequences of cachexia [II, B].
 Cachexia treatment requires a multimodal approach
aimed at relieving symptoms impacting on food intake,
ensuring adequate energy and nutrient intake, minimis-
ing catabolic alterations, supporting muscle training
and offering psychological and social support [II, B].
 During anticancer treatment and in patients with a life
expectancy of more than a few (i.e. 3-6) months, inter-
ventions to both antagonise deterioration of body re-
sources and metabolism, and to alleviate debilitating
symptoms, are recommended [IV, B].
 If expected survival is less than a few (i.e. 3-6) weeks,
focussing on anti-cachexia interventions aimed at allevi-
ating distressing symptoms like thirst, nausea, vomiting
and dysphagia, and psychological and existential distress,
as well as distress to family members, is recommended
[IV, B].
 In situations where it is difficult to decide on appropriate
anti-cachexia intervention strategies, a tentative inter-
vention for a limited period may be considered to eval-
uate the likelihood of improvement [IV, C].NUTRITIONAL INTERVENTIONS
In patients undergoing anticancer therapy and/or with an
expected survival of at least a few months, ensuring an
adequate energy and nutrient intake should be pursued
vigorously (see section on nutritional requirements). Cancer
patients who cannot eat adequate amounts of food should
receive nutritional support as an essential component of
best supportive care to improve food intake, BW and
QoL.30-32 Nutritional support in patients able to eat should
be based on dietary counselling, guidance on choosing high-
energy, high-protein foods, enriching foods (e.g. by adding
fat/oils, protein powder) and use of oral nutritional sup-
plements (ONSs). If this proves inadequate, tube feeding
should be offered if the lower GI tract is working, otherwise
PN is the method of choice. Separate routes of feeding may
be combined for optimal effect7 (Figure 5).
In patients not receiving anticancer therapy with an ex-
pected survival of less than a few months, nutritional in-
terventions with low risks/burdens for the patient (e.g.
counselling and ONSs) are preferred. Very few trials have
compared different modes or amounts of nutritional sup-
port. In one trial, which randomised patients with severely
compromised food intake and a limited survival of 1-4
months to supplemental PN or oral feeding, PN did not
improve QoL or survival but increased adverse events.33
Similarly, another trial which randomised patients in the
end-of-life setting to PN or fluids only showed that PN did
not affect median survival.34 During the last weeks of life,
nutritional interventions are rarely indicated.7 Given the
potential risks of enteral nutrition and PN (see sections on
tube feeding and PN), these interventions should beVolume 6 - Issue 3 - 2021considered as high-risk compared with low-risk in-
terventions such as counselling and ONSs.
Nutritional requirements
The aim of nutritional support is to ensure adequate intake
of energy and nutrients by enabling the patient to eat
normal food, enjoy eating and participate in meals with
others as a component of social life.7 It may be difficult or
even impossible to achieve tissue accretion without physical
activity and within the context of active systemic inflam-
mation; therefore, these problems need to be addressed
simultaneously.
While resting energy expenditure may be increased in
cachexia, total energy expenditure is often normal (25-30
kcal/kg BW/day) because of corresponding reductions in
physical activity,7 but may be unpredictably low or high in
some patients.35 Even increased energy and protein intake
may not be able to attenuate weight loss in all patients.
Given the presence of anabolic resistance in older subjects
and in chronic diseases, higher than normal amounts of
protein (at least 1.2 and possibly up to 2 g/kg BW/day) may
be required to balance protein synthesis.36-38
Fat utilisation in weight-losing cancer patients is very
efficient and may cover a major part of resting energy
expenditure,39,40 whereas carbohydrate utilisation is
impaired in the presence of systemic inflammation and in-
sulin resistance. In addition, fats are energy-dense and
allow for feeding of smaller volumes. Compared with
standard food, an isonitrogenous, isocaloric, ketogenic diet
low in carbohydrates maintains nitrogen balance and
whole-body protein turnover rates.41 In a randomised
controlled trial (RCT) carried out in malnourished cancer
patients, a high-fat diet improved weight control, fat-free
mass and body mass compared with normal food.42
Dietary counselling and ONSs
It is unreasonable to expect an increase or stabilisation in
weight if nutritional needs are not met. As a good example,
two systematic reviews have shown that dietary counselling
is generally effective in increasing dietary intake, BW and
QoL in patients undergoing radiotherapy, with some sug-
gestion that dietary counselling may also improve nutrition
impact symptoms, complications, response to anticancer
treatment and survival.43,44
ONSs are a balanced mixture of macro- and micro-
nutrients available as liquid feeds, puddings and
powdered formulations reconstituted with milk or water.
They are available in a range of different presentations,
flavours and formulations, including fibre-containing and
milk-, juice- or yoghurt-like products. In general, dietary
counselling with ONSs, when necessary, is effective for
inducing weight gain and increasing dietary intake. How-
ever, most trials on this topic were hampered by poor
methodological quality, specifically from inadequate
reporting of actual dietary intake and not reaching recom-
mended dietary intakes.32,45 Three systematic reviews re-
ported that providing standard ONSs without dietaryhttps://doi.org/10.1016/j.esmoop.2021.100092 7
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Figure 5. Choosing nutritional intervention options.
Purple: symptom; turquoise: nutritional interventions; white: other aspects of management.
EN, enteral nutrition; GI gastrointestinal; NTF, nasogastric tube feeding; ONS, oral nutritional supplement; PEG, percutaneous endoscopic gastrostomy; PN, parenteral
nutrition.
ESMO Open J. Arends et al.counselling was not effective.43,44,46 As such, ONSs are best
used as an adjunct to a therapeutic diet and counselling by
a professional dietician.46 A meta-analysis of patients un-
dergoing chemotherapy showed positive effects of dietary
counselling on weight gain with or without ONSs.32 Two
systematic reviews focusing on dietary counselling and
ONSs in malnourished patients reported positive effects on
energy intake, weight gain and some aspects of QoL (e.g.
emotional functioning, loss of appetite and global QoL) but
noted that evidence was weak due to the poor methodo-
logical quality of included trials.30,47
In cancer cachexia, n-3 fatty acids have been studied,
particularly for their anti-inflammatory properties, and are
available as a component of specialised ONSs, usually also
enriched in protein (N3P-ONSs). Several randomised trials
have been published on the effects of N3P-ONSs in cancer
patients.32,47-50 Overall, studies were heterogeneous and
inadequately powered to show effects on treatment toxicity
or survival. No negative effects of the supplements were
reported. Most trials suggested benefits of N3P-ONSs on
weight, lean body mass and some aspects of QoL when
given to patients receiving radiotherapy, chemotherapy or
chemoradiotherapy. However, when given to patients not
receiving anticancer therapy, no benefit of N3P-ONSs was
detected.518 https://doi.org/10.1016/j.esmoop.2021.100092Tube feeding
Dysphagia due to obstruction, motility dysfunction or
mucosal inflammation may compromise or prevent normal
food intake and thus is an indication for tube feeding to
circumvent the defect. Patients with head and neck or up-
per GI cancers are at particular risk of dysphagia due to
obstructing tumours as well as severe mucositis induced by
aggressive treatment (e.g. combined-modality treatment).
It is critical to recognise the emergence of dysphagia early
and to respond in a timely and individually appropriate way
to safeguard adequate feeding. This may include diagnostic
procedures to classify and grade swallowing deficits,
involving a speech therapist, specialised dietary counselling
and products either via nasogastric tube feeding (NTF) or
percutaneous tube feeding [e.g. percutaneous endoscopic
gastrostomy (PEG)].7,52
Tube feeding may be associated with potentially serious
complications, including mechanical (e.g. tube blockage), GI
(e.g. diarrhoea), infectious (e.g. aspiration pneumonia) and
metabolic (e.g. refeeding syndrome) complications.53
Short-term RCTs have shown that the metabolic efficacy
and complication rates of enteral nutrition and PN are
similar.54,55 As the enteral route is more physiological, safer
and less expensive, it represents the first option if there is
no severe impairment of GI function (Figure 5). In someVolume 6 - Issue 3 - 2021
J. Arends et al. ESMO Opensettings, supplemental PN should be preferred over tube
feeding; for example, if patients are suffering from nausea,
vomiting, abdominal discomfort or severe diarrhoea. Tube
feeding may be ineffective due to frequent dislodging; in
particular, tube feeding may not prevent aspirations in pa-
tients with dysphagia. Given the lack of reliable clinical
evidence of superior outcome for either method, it has
been proposed that patient preference be considered when
deciding on the feeding method.56 Some patients strongly
prefer an intravenous route over tube feeding,56,57 espe-
cially if a patient has already had a central venous catheter
inserted.
Results from observational trials and RCTs comparing
early tube feeding to oral nutrition in patients with head
and neck cancer are heterogeneous, possibly due to the
different oral nutrition regimens used in the control groups
as well as a lack of stratification of patients by risk scores for
malnutrition and dysphagia.58 Appropriate prediction and
careful monitoring of food intake in order to identify the
need for initiation of enteral feeding are recommended by
European and Canadian guidelines.7,59
Several RCTs have compared NTF and PEG in head and
neck cancer patients requiring nutritional support for 1
month. PEG resulted in better nutritional parameters after 6
weeks of treatment but not later.60,61 Meta-analyses have
also reported no significant differences in the overall
complication rates between NTF and PEG,62 even though
tube dislodgement was more frequent with NTF and
dysphagia was more frequent with PEG.63 Resolution of
dysphagia is impaired with long-term tube feeding.PN
In patients with severely compromised GI function, it may
be impossible to ensure adequate nutrition by the oral or
enteral route. PN and home PN are being widely used in
patients with advanced cancer, both in patients still
receiving or no longer receiving anticancer treatments,
although evidence to support PN in patients with advanced
cancer is weak.33,64-66 It appears obvious that a prolonged,
severely reduced tolerance of food may compromise clinical
outcome, and in these settings, PN might improve QoL and
possibly survival. A recent systematic review assessing the
effectiveness of home PN in people with malignant bowel
obstruction included only observational studies, reported a
high risk of bias and graded the certainty of evidence to be
very low for improving survival and QoL.67 Another sys-
tematic review found that PN in patients with advanced
cancer was understudied and that the level of evidence was
weak.68 The PS and Glasgow Prognostic Score impact
strongly on survival in patients with advanced cancer
receiving home PN.69 From this, it has been suggested that
PN should be avoided if the ECOG/WHO PS is 3 or 4.70 More
complex scores and nomograms have been developed to
estimate the probability of survival in patients with
advanced cancer receiving home PN, e.g. based on GlasgowVolume 6 - Issue 3 - 2021Prognostic Score, PS, presence of metastatic disease and
cancer entity.65 While these tools may separate groups of
patients with similar survival, predictions for individual pa-
tients are imprecise.
However, absence of evidence is not identical to evidence
of absence of an effect,71 and a decision to forego the
option of intravenous nutrition should not only be based on
the lack of high-quality trials. Rather, the decision to initiate
PN should be individualised based on the extent of disease,
physical and psychological resources of the patient and on a
case-by-case risk/benefit assessment (see Table 3).
PN carries the risk of potentially severe complications,
including (but not limited to) catheter-related infection,
occlusion and thrombosis, derangements of substrate and
electrolyte levels, refeeding syndrome, exsiccosis, fluid
overload and chronic hepatopathy and osteopathy.72
PN may be offered to patients who do not tolerate any
oral food or those who still tolerate some but inadequate
amounts of oral food. The latter has been termed ‘sup-
plemental PN’, although there is no agreement on the
amount of food tolerated to justify this designation. A
number of prospective observational studies have re-
ported the effects of PN in patients with advanced cancer
suffering from either severe GI obstruction or malnutri-
tion.66,73-75 OS was reported as 57%-75% after 1 month,
34%-67% after 3 months and 12%-34% after 6 months,
but this was dependent on the type of patients
included.66,73,75 Only one of these observational trials
reported a small, but not clinically relevant, improvement
in QoL.73 Obling et al.76 randomised 47 patients with
incurable GI cancer to dietary counselling plus either ONSs
or supplemental PN. The authors observed improvements
in fat-free mass and QoL in favour of the supplemental PN
group at 12 weeks but no difference in 6-month survival;
however, the statistical analysis was flawed by the very
large number of statistical tests carried out.76 Bouleuc
et al.33 randomised 111 patients with advanced cancer to
optimised nutritional care with or without additional
supplemental PN for several months; supplemental PN did
not improve either QoL or survival but increased severe
adverse events. Thus, the potential clinical benefit of PN
needs to be balanced against relevant risks (e.g. metabolic
derangements, septic complications) and burdens (e.g.
connection to an intravenous line for up to 14 hours per
day).33
None of the published trials reported whether patients
were aware of their prognosis or the uncertainty about the
benefits of PN.
An open question is how to manage the withdrawal of
home PN at end of life. Although there has been no formal
study on this issue, clinical experience shows that general
criteria to withhold home PN when deemed no longer
helpful should be considered early at the time when home
PN is first offered and thereafter be discussed repeatedly to
minimise distress when it is required to phase out PN at end
of life.https://doi.org/10.1016/j.esmoop.2021.100092 9
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Nutritional interventions
 In patients with inadequate food intake, nutritional inter-
ventions are recommended. In patients with an expected
survival of more than several months and in those
receiving anticancer therapy, these interventions should
be escalated, as required. In other situations, low-risk
interventions (e.g. counselling and ONSs) are preferred
[II, A].
 If safe, the oral route should be the first option for nutri-
tional support. Enteral tube feeding may be used in cases
of dysphagia if the small bowel function is preserved. PN
should be considered if oral intake and tube feeding are
not tolerated or remain inadequate [II, A].Nutritional requirements
 Nutritional interventions should aim to fulfil energy and
nutrient requirements [III, B].
 Nutritional interventions should be accompanied by mus-
cle training and efforts to normalise metabolic state
(diminish systemic inflammation, alleviate distress) [III, B].
 To maintain nutritional status, at least 25-30 kcal/kg BW/
day is recommended, adjusting the regimen as required
[V, B].
 At least 1.2 g protein/kg BW/day should be provided [V,
B].
 In patients with cachexia, regimens with fat accounting
for half of the non-protein calories are recommended
[II, B].Dietary counselling and ONSs
 Dietary counselling should be the first choice of nutri-
tional support offered to improve oral intake and
possibly weight gain in cachectic or at-risk patients
who are able to eat. Dietary counselling should empha-
sise protein intake, an increased number of meals per
day, treatment of nutrition impact symptoms and offer-
ing nutritional supplements when necessary. An
adequately trained professional should guide this advice
[II, B].
 ONSs can be supplied as part of dietary counselling to
improve energy intake and induce weight gain [II, B].
 Patients receiving chemotherapy, radiotherapy or che-
moradiotherapy may be offered N3P-ONSs to increase
BW, attenuate loss of lean body mass and improve QoL
[II, C].Tube feeding
 For patients with head and neck or upper GI cancers,
especially those undergoing anticancer treatment, tube
feeding to maintain BW or to reduce weight loss is10 https://doi.org/10.1016/j.esmoop.2021.100092recommended if oral feeding including ONSs is expected
to remain inadequate for more than a few days [I, A].
 In patients requiring >4 weeks of enteral feeding, PEG
rather than NTF is recommended [II, C].
 In patients requiring tube feeding, screening for and
management of dysphagia is recommended along with
encouragement and education to patients regarding
how to maintain their swallowing function [II, B].PN
 Home PN should be offered to patients if their QoL and/
or length of survival is expected to be severely compro-
mised by progressive malnutrition. Indicators of a poten-
tial benefit are ECOG/WHO PS 0-2, a low level of
systemic inflammation (normal levels of serum albumin,
modified Glasgow Prognostic Score <2) and the absence
of metastatic disease [V, B].
 There is insufficient evidence to routinely recommend
supplemental PN in hypophagic, malnourished patients
receiving chemotherapy to improve QoL and nutrition
parameters [V, B].MUSCLE STRENGTH AND ENDURANCE TRAINING TO
SUPPORT ANABOLISM
Current evidence shows that physical exercise is safe and
provides benefit in QoL and in muscular and aerobic
fitness for people with cancer, both during and after
treatment.77 However, so far, reviews on exercise in cancer
cachexia have generally been narrative or based on animal
models. A systematic review and meta-analysis of RCTs
focusing on exercise training in cachexia found no trials
which met the inclusion criteria.78 An RCT comparing 8
weeks of exercise training with usual care in 231 patients
with advanced cancer reported improved physical perfor-
mance but no effect on subjective fatigue.79 However,
despite limited robust data, multimodal rehabilitation
programmes incorporating exercise and nutritional
interventions have been reported to improve many out-
comes, most notably those relating to physical endurance
and depression scores.80
While many patients with advanced cancer may drop out
of exercise programmes due to progressive disease, when
carefully supervised, the intervention appears safe for
patients with advanced cancer, even in the hospice
setting.79,81,82 It is suggested that exercise techniques be
chosen based on the individual risk of falls and of skeletal
instabilities, and to suspend training when patients experi-
ence a fever >38C, infection, platelet count <20 000 g/l,
haemoglobin <8 g/dl or if they display other contraindi-
cations to exercising.83
Exercise has been hypothesised to attenuate the effects
of cancer cachexia by modulating muscle metabolism, in-
sulin sensitivity, anaemia, hypogonadism and systemic
inflammation.84 Physical activity may increase muscleVolume 6 - Issue 3 - 2021
J. Arends et al. ESMO Openstrength and maintain a patient’s functional ability, espe-
cially when a combination of moderate- to high-intensity
resistance and aerobic exercise is undertaken.84 Exercises
of moderate intensity are described as those which fall in
between 5-8 metabolic equivalents (METS; a procedure to
quantify the energy cost of activities). These include activ-
ities that take as much effort as brisk walking (5 km/h),
a stationary bike with light effort and home-based exer-
cises.85 Resistance exercises should alternate between up-
per and lower limbs, focus on movement quality and use
defined sets of repetitions. Aerobic training should be
accompanied by continuous or intermittent heart rate
monitoring.
Recommendations
 When guided by professional experts, moderate physical
exercise is safe in patients with cancer cachexia and is
recommended to maintain and improve muscle mass
[II, B].
 Resistance exercise two to three times per week as well
as moderate aerobic (endurance) training should be
offered to all patients with cachexia. The exercise pre-
scription should involve a physiotherapist or an
adequately trained professional and comprise a struc-
tured approach, including mode (aerobic, resistance,
flexibility), frequency, intensity and duration as well as
defined time points for reassessment [II, B].PHARMACOLOGICAL INTERVENTIONS
Several drugs have been investigated for their potential use
to treat or ameliorate the consequences of cancer cachexia.
However, only corticosteroids and progestins have consis-
tently shown beneficial effects on appetite and/or BW,
though at the expense of substantial side-effects, while for
other agents, the data are heterogeneous or disappointing.
The following section presents drugs that are approved
for clinical use and have shown some anti-cachexia effect in
clinical trials.
Corticosteroids
Corticosteroids include several agents with variable gluco-
corticoid, mineralocorticoid and anti-inflammatory potency.
Prednisolone, methylprednisolone and dexamethasone are
used most frequently. Symptomatic relief appears to be
mainly achieved by their potent anti-inflammatory activ-
ity.86 Toxicity is usually minor when used for only a few
weeks, whereas during prolonged intake, corticosteroids
cause a rapid loss of muscle mass, insulin resistance and
increased likelihood of infections, such as candida and
stomatitis, contributing to a deterioration of cachectic pa-
tients.87 Corticosteroids are recommended for the control
of cancer-related fatigue.88 Several RCTs investigating the
effects of corticosteroids on appetite in patients with
advanced cancer have been published. Most trials reported
a temporary benefit in appetite and well-being, whereasVolume 6 - Issue 3 - 2021there were no effects on BW or survival.7,89 The anti-
anorectic effect of corticosteroids is transient and often
disappears after a few weeks.90 There are limited data
available to recommend one corticosteroid over another.
Progestins
Medroxyprogesterone acetate and megestrol acetate (MA)
have been studied widely to treat weight loss and anorexia
in cancer patients. In preclinical models, progestins stimu-
late appetite and inhibit the synthesis of pro-inflammatory
cytokines. A Cochrane review91 including 23 RCTs on the use
of MA in patients with cancer (median duration of 8 weeks)
found a significant improvement in appetite (relative risk
2.57) and weight gain (relative risk 1.55). However, no
consistent improvement in QoL was observed and no data
on muscle mass or physical function were reported. In the
analysed trials, MA was used in doses of 160-800 mg/day
and weight improvement appeared higher for doses >160
mg/day, while no dose effect was observed for appetite.
Treatment with MA is associated with an increased risk of
thromboembolism, fluid retention, adrenal insufficiency and
hypogonadism in male patients.92 While the aforemen-
tioned Cochrane review reported that MA treatment was
associated with an increased mortality rate,91 an update
concluded that MA does not increase the rates of adverse
events or death.93
Although progestins have been studied in many RCTs,
confirming modest stimulation of appetite, their clinical use
is limited because of the significant risk of potentially
serious side-effects.
Cannabinoids
Cannabis sativa is a medical plant containing multiple
cannabinoids, including tetrahydrocannabinol (THC). Medi-
cal cannabis is available in various formulations, e.g. tab-
lets/capsules, vaporiser or mouth spray.
In patients with cancer cachexia, when studied in small
trials and case series, THC appeared to improve appetite
and attenuate weight loss. However, larger randomised
trials comparing THC with either MA94 or placebo95 could
not detect a significant effect on appetite or QoL; in these
trials, toxicity was low. In a small, placebo-controlled, 8-
week RCT in 47 anorectic patients with advanced non-
small-cell lung cancer, the synthetic THC derivative,
nabilone, resulted in low toxicity but no significant effects
on appetite or QoL.96 Current safety data for medical
cannabis in cancer cachexia is based on only a few trials
that likely under-dosed patients and so safety concerns
remain.
Androgens
In cancer patients, hypogonadism is related to advanced
cancer status, weight loss and, most likely, the use of opioid
therapy. Anabolic-androgenic steroids have been shown to
ameliorate loss of muscle mass and strength in patients
with wasting associated with acquired immune deficiencyhttps://doi.org/10.1016/j.esmoop.2021.100092 11
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extensively in patients with cancer cachexia. In an RCT of 37
lung cancer patients, the analogue nandrolone did not
improve BW compared with placebo.97 In a three-armed
RCT including 496 patients with cachexia, fluoxymesterone
10 mg b.i.d. was significantly inferior to MA 800 mg/day in
terms of appetite improvement.98
Olanzapine
Olanzapine is an atypical antipsychotic drug acting on
multiple receptors, including dopamine and serotonin re-
ceptors, both of which are potentially relevant in
cachexia.99 In clinical use, olanzapine causes more weight
gain than other antipsychotic drugs.100 In a single arm, dose
escalation study in 39 weight-losing patients with advanced
cancer, olanzapine could not attenuate weight loss.101
However, in a trial randomising 80 patients with advanced
cancer to receive MA or MA and olanzapine, the combi-
nation arm yielded significant improvements in appetite
and BW.99 In a recent RCT, olanzapine significantly reduced
non-chemotherapy-induced nausea in 30 patients with
advanced cancer compared with placebo.102 Thus, olanza-
pine may be considered for treating chronic nausea in pa-
tients with advanced cancer.
Non-steroidal anti-inflammatory drugs
Non-steroidal anti-inflammatory drugs (NSAIDs) block the
cyclooxygenase pathways and reduce inflammation by
inhibiting prostaglandin production. NSAIDs have been
studied to reduce the catabolic drive of systemic inflam-
mation in patients with advanced cancer and cachexia. In a
systematic review including six controlled trials and seven
observational trials,103 11 of these trials reported an in-
crease or stabilisation of BW or lean body mass with few
side-effects reported. The cumulative evidence, however,
was weak due to the low methodological quality of the
analysed trials. Thus, in cachectic patients requiring pain
control, NSAIDs could be considered with the potential
additional benefit of improving BW.
Prokinetics
Metoclopramide and domperidone are widely used to treat
early satiety and chronic nausea104 as well as dyspepsia
syndrome and gastroparesis.105 However, no large RCT has
investigated the role of prokinetic agents in cachexia. While
one RCT in patients with advanced cancer showed that
metoclopramide may improve nausea but not appetite,106
there are no similar studies with domperidone.
Metoclopramide and domperidone can cause serious,
mainly neurological, side-effects, e.g. tardive dyskinesia,
spasms, depression, dizziness and urinary retention.107
Ghrelin receptor agonists
Anamorelin has recently been approved in Japan for
cancer cachexia in patients with non-small-cell lung cancer,
gastric cancer, pancreatic cancer and colorectal cancer,12 https://doi.org/10.1016/j.esmoop.2021.100092but it is not approved in Europe based on findings from
the ROMANO studies which showed a more modest
improvement in lean body mass compared with that seen
in the Japanese trials.Combination therapy
Published trials investigating potential synergies among
pharmacological agents like progestins, antioxidants, L-
carnitine, thalidomide, n-3 fatty acids and NSAIDs were
unsuccessful or unreliable due to methodological
deficiencies.108,109Recommendations
 Corticosteroids may be used to increase appetite for a
short period of up to 2-3 weeks. Effects on appetite usu-
ally disappear with longer treatment [I, B].
 Progestins may be used to increase appetite and BW, but
not muscle mass, QoL or physical function in patients
with cancer cachexia [I, B]. The risk of serious side-
effects, including thromboembolic events, must be
considered.
 There is insufficient evidence to support the use of med-
ical cannabis or its derivatives to alleviate anorexia or
early satiety in patients with cancer cachexia [II, C].
 As there is evidence of no beneficial effect in terms of
improvement in muscle mass, androgens are not recom-
mended [II, D].
 There is moderate evidence to suggest considering the
use of olanzapine to treat appetite and nausea in pa-
tients with advanced cancer [II, B].
 There is insufficient evidence to recommend the use of
NSAIDs alone to treat cancer cachexia [III, C].
 There is insufficient evidence to recommend the use of
metoclopramide or domperidone alone to treat cancer
cachexia [II, C].
 There is insufficient evidence to recommend specific
combination regimens due to the lack of evidence
from large, well-designed, randomised trials [II, C].COMMUNICATION WITH PATIENTS AND THEIR FAMILIES
Addressing cachexia-related psychosocial distress
In the presence of cachexia-related symptoms such as
anorexia and fatigue, patients and their families experience
stressful changes in eating habits and challenging social
interactions.110,111 Patients report wanting and trying to eat
but being unable to do so, while family members often
misunderstand the complex and powerful derangements
responsible for anorexia and food aversion in cachexia and
pressure their relative to eat, thus increasing tension and
conflict in the patientefamily unit.112,113 In addition,
continued loss of weight and function alters the patient’s
appearance with consequences on their self-image and self-
esteem.113Volume 6 - Issue 3 - 2021
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impact of cachexia allows for timely interventions to
manage distressing symptoms and improve QoL.114
Cachexia-centred communication
Focus groups and semi-structured interviews with 34 Irish
health care professionals revealed that doctors, nurses and
dieticians tend to avoid the problem of cancer cachexia
because of difficulties in communicating its complex and
often irreversible nature and negative prognosis, and for
fear of lowering the patient’s hope.115 A missed acknowl-
edgement, however, has made family members feel mis-
informed and isolated.116 Poor communication by health
care professionals may weaken the confidence of patients
and families in their knowledge and understanding of
cachexia; thus, transparent information is clearly
preferred.116 A large survey (response rate 76%) of 702
bereaved family members of cancer patients in Japan sug-
gested that health care professionals may relieve psycho-
logical and emotional distress by explaining the mechanisms
of cancer cachexia as simply as possible.117
Tailored information about the role of nutritional support
according to the stage of cachexia (see Figure 3) is funda-
mental to achieving agreement between health care
professionals, patients and families on treatment goals. A
systematic review including 19 studies investigating eating-
related distress in patients with cachexia found that the
main causes of negative psychosocial effects are a lack of
knowledge regarding the nature of cancer cachexia and
unsuccessful attempts to increase BW. A structured and
informative intervention prevents families from feeling
overwhelmed by their loved one’s disease and alone in
managing weight and eating problems.118
These findings suggest that patients and their families
need honest and problem-centred communication tailored
to the disease stage.
Psychosocial interventions
The aim of psychosocial interventions is to reduce the
emotional burden associated with cancer cachexia by
empowering patients and families to cope with the dys-
functions and derangements of cachexia, thus improving
QoL.118-120 Health care professionals can adopt different
strategies (e.g. DVDs, stories, open questions) to help pa-
tients and families to share their perspectives about food-
related issues.120
A small, randomised, exploratory trial evaluating psy-
chosocial intervention on weight and eating-related
distress in 50 patients with advanced cancer found that
treated patients reported lower levels of distress
compared with the control group.118 Qualitative analysis
suggested that psychosocial intervention was helpful for
carers as it provided information, reassurance and support
for self-management.119 In a small, mixed-methods, qual-
itative research study, a family-centred psychosocial
intervention was developed and delivered by a single
nurse researcher to help patients with advanced cancerVolume 6 - Issue 3 - 2021and their families/caregivers to cope with the patient’s
involuntary weight loss and worsening appetite. The
intervention was delivered during face-to-face consulta-
tions and 15 out of 16 patientecaregiver dyads reported
benefits.120Recommendations
 Health care professionals should routinely assess pa-
tients and their families to permit timely identification
of any psychosocial distress [V, B].
 Health care professionals should provide tailored infor-
mation according to the stage of cachexia and empower
patients and their families to understand its nature,
course and biological mechanisms, and to acknowledge
its negative effects (e.g. weight loss, reduced appetite,
early satiety), thereby promoting greater awareness
about the clinical condition and the need for early multi-
disciplinary intervention [IV, B].
 Psychosocial interventions should be considered as early
as possible in cachexia management. They should be
conducted by trained health care professionals and aim
to help patients and their families to cope with involun-
tary weight loss and to strengthen the dyadic coping re-
sources [III, B].MULTIMODAL TREATMENT
Multimodal interventions against cancer cachexia have
been advocated for more than a decade based on the
complex underlying pathophysiology [see Section 2 (text
and Supplementary Figure S2) of the Supplementary
Material, available at https://doi.org/10.1016/j.esmoop.
2021.100092] and the wealth of contributing factors
impacting on BW, muscle mass, food intake and physical
function.121 Components of such multimodal support may
target calorific intake, physical activity, psychosocial and
spiritual functions, as well as key factors in cachexia path-
ophysiology, such as inflammation. The concept of using
synergies of supportive interventions has been described to
achieve ‘anabolic competence’.122 Examples of multimodal
care in daily clinical practice have been assembled by
Maddocks et al.123 However, so far, few trials combining
separate treatment modalities have been reported; ongoing
investigations primarily focus on simultaneously targeting
nutritional support, muscle training and anti-inflammatory
concepts. Importantly, in healthy subjects, bouts of phys-
ical exercise significantly prolong the increase in muscle
protein synthesis induced by feeding.124
The randomised, 6-week, MENAC pilot trial compared a
multimodal combination of NSAIDs, nutritional advice, oral
supplements enriched in eicosapentaenoic acid and physical
exercise to standard treatment in 46 patients with solid
tumours starting chemotherapy.82 This trial showed that the
intervention improved BW and is now being followed by a
phase III trial recruiting patients with lung and pancreatic
cancer. Another small trial, randomising 58 patients with
advanced cancer to usual care or 12 weeks of an exercisehttps://doi.org/10.1016/j.esmoop.2021.100092 13
ESMO Open J. Arends et al.training programme combined with repeated nutritional
counselling, showed a significant increase in protein intake
and a decrease in nausea and vomiting.125 Recently, a large
RCT including 328 patients with previously untreated met-
astatic oesophago-gastric cancer received either standard
care or additional nutritional and psychological in-
terventions; combined-modality support resulted in
improved OS in the intention-to-treat analysis.126
Recommendation
 In patients with cachexia, combining nutritional support
with exercise training and psychological support is pro-
posed [II, B]. Anti-inflammatory interventions should
also be considered [V, C].ORGANISING SUCCESSFUL CACHEXIA CARE IN MODERN
ONCOLOGY
Critical points for cachexia care are to implement screening,
assessment and treatment in routine cancer care. Initiating

















Figure 6. Responsibilities and interactions of members of the multimodal care tea
GI, gastrointestinal.
Solid line arrows depict responsibilities. Dashed line arrows depict interactions. Furthe
will frequently be necessary.
14 https://doi.org/10.1016/j.esmoop.2021.100092process, requires support by the institutional leadership.
Evidence for the effectiveness of cachexia clinics is scarce
due to a lack of RCTs.127 Extrapolation from pain in-
terventions128 or specialised palliative care129 suggests its
potential effectiveness. Typically, a registered dietician,
physiotherapist, palliative care nurse, psychologist and a
palliative/supportive/rehabilitative care specialistdwho
ideally would also be a medical oncologist130dcould build
the ‘inner circle’ of a cachexia clinic or team (Figure 6). A
close integration of these professionals within the cancer
clinic (e.g. case discussions, tumour boards, clinical rounds,
education, clinical trials), as well as access to specialised
professionals such as gastroenterologists (e.g. for vent,
stent, gastrostomy, jejunostomy), head and neck specialists,
logopaedic experts and invasive pain specialists, is highly
recommended.Recommendations
 Screening for cachexia should be integrated into routine
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linked to immediate access to cachexia care interven-
tions [V, B].
 Cachexia care should be delivered utilising a combination
of nutrition, physical activity, psychological, oncological,
palliative/supportive/rehabilitative care and oncologist
competencies [V, B].METHODOLOGY
This CPG was developed in accordance with the ESMO
standard operating procedures for CPG development
(https://www.esmo.org/guidelines/esmo-guidelines-method
ology). The relevant literature has been selected by the
expert authors. Levels of evidence and grades of recom-
mendation have been applied using the system shown in
Supplementary Table S3, available at https://doi.org/10.
1016/j.esmoop.2021.100092.131 Statements without
grading were considered justified standard clinical practice
by the experts.
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